---
title: PGDIS 2024
subtitle:  ðŸ“… May 6-8 2024 ðŸ‡²ðŸ‡¾ Kuala Lumpur, Malaysia 
title-slide-attributes: 
  data-background-image: venue.JPG
  data-background-opacity: "0.5"
image: venue.JPG
author: 
  - Marie
  - Kayleigh
  - Xuyang
date: 2024-05-22
format: 
  revealjs:
    theme: [beige, custom.scss]
    progress: true
    incremental: false
    link-external-icon: true
    link-external-newwindow: true
    controls: true
    touch: true
    slide-number: true
    chalkboard:
      theme: chalkboard
      boardmarker-width: 5
      chalk-width: 2
      chalk-effect: 1.0
---

## Conference Agenda {background-video="slidebg.m4v" background-video-loop="true" background-video-muted="true" background-video-size="cover" background-opacity="0.7"}

::: {.incremental .highlight-last}
- Day 0 (Sun): Pre-conference workshop (Thermo Fisher PGT solutions, carrier screening, methylation, TGS)
- Day 1 (Mon): Advances in PGT + Contraversies in PGT
- Day 2 (Tue): Contraversies in PGT + Embryo selection + niPGT + genetic counselling + Gala dinner
- Day 3 (Wed): Quality in IVF + Inovations in Preimplantation Genetics
:::


## [Thermo Fisher Scientific]{.underline}'s NGS Solutions For PGT

::: {style="font-size: 0.8em;"}
Whole Workflow: Lab Prep + Sequencing + Analysis + Reporting

- Library Prep [(DNA extraction, WGA and barcoding)]{style="color: gray"} and Template Prep [(automated clonal amplification)]{style="color: gray"}
  - [Ion Chefâ„¢ System](https://www.thermofisher.com/order/catalog/product/4484177){.external}
- Sequencing (Ion Semiconductor Sequencing): 
  - [Ion GeneStudioâ„¢ S5 System](https://www.thermofisher.com/no/en/home/life-science/sequencing/next-generation-sequencing/ion-torrent-next-generation-sequencing-workflow/ion-torrent-next-generation-sequencing-run-sequence/ion-s5-ngs-targeted-sequencing.html){.external}
  - [Ion Torrent Genexusâ„¢ System](https://www.thermofisher.com/no/en/home/life-science/sequencing/next-generation-sequencing/ion-torrent-next-generation-sequencing-workflow/ion-torrent-next-generation-sequencing-run-sequence/ion-torrent-genexus-system.html){.external}
- Analysis and Reporting: 
  - [Ion Reporterâ„¢ Software](https://ionreporter.thermofisher.com/ir/){.external}
:::

## PGT-A {.smaller}
### [Ion ReproSeqâ„¢ PGS](https://www.thermofisher.com/no/en/home/life-science/sequencing/next-generation-sequencing/ion-torrent-next-generation-sequencing-applications/reproductive-health-research/preimplantation-genetic-testing/preimplantation-genetic-screening.html)
- Detect whole-chromosome, mosaic, and small copy number events with just 6 pg of DNA from single or multiple cells
- Multiple kit configurations to analyze from 16 to 192 samples in a single run
- Mosaicism detection, gender masking, and improved data plotting (for easier data interpretation)
- Together with the _Ion AmpliSeqâ„¢ Polyploidy Panel_ can confidently identify triploidy 69, XXX, assess potential maternal contamination, and track sibling samples, preventing sample mix-ups.
- Turnaround time for the Ion ReproSeq PGS Kit 16 samples/run is <10 hours with <2 hours of hands on time.

## PGT-M
#### [PGD-SEQâ„¢ Panel and Reagent Kits](https://www.thermofisher.com/no/en/home/life-science/sequencing/next-generation-sequencing/ion-torrent-next-generation-sequencing-applications/reproductive-health-research/preimplantation-genetic-testing/targeted-ngs-monogenic.html)
- \>500 gene panels for common and rare monogenic diseases for IVF 
- Complete kit reagents and targeted PGT-M library to analyze 15 samples
- Comprehensive familial carrier status using proprietary linkage analysis software
- >**Simultaneous PGT-M and PGT-A using a single embryo biopsy**

## Epigenetics Testing
Preimplantation DNA methylation Screening (**PIMS**)

- Current PGT mainly focus on genetic causes
- Only about 1/3 of birth defects can find reasons
- Both genetic and epigenetic factors can cause birth defects
- Compared to standard PGT-A, PIMS increases pregnancy rate and live birth rate by 10-15%
- Exclusive methylation-based **artificial intelligence** to improve accuracy and to avoid subjectivity


## Mosaisism {.smaller}


- IRMET (international registry of mosaic embryo transfer) (irmet.net)
- Kilder til mossaikk: endogene, indusert, artifaktisk
- 20-30% mosaikk-tilstander er alt for hÃ¸yt - mÃ¥ da finne avvik (RMA, lab/operatÃ¸r, osv)
- Gold standard: celle linjer (blinded?), brukes for Ã¥ validere og definere â€œcut offâ€/stÃ¸y hos oss
- KjÃ¸re OM alle segmentale aneueploidier (Rana et. Al, 2023; D. Marin)
- Hvordan rapporteres dette?
- Det er caser med uheldige utfall, med disse er undertrykt/ikke publisert pga juridiske problemer


## Mosaikk
![](mosaikk.png)

## Mosaikk fort.
![](mosaikk_fort.png)

## Mosaikk fort.
![](mosaikk_fort_1.png)

## Mosaikk, rapportering
[Mosaikk-embryo klassifisering for et redusert embryotap, v/Steve Grkovic (genea, Australia)]{style="font-size: 0.5em;"}
![](mosaikk_rapport.png)

## mosaikk, rapportering
![](mosaikk_rapport_1.png)


## mosaikk, rapportering

:::: {.columns}
::: {.column width=50%}
![](mosaikk_rapport_2.png)
:::

::: {.column width=50%}
![](mosaikk_rapport_3.png)
:::
::::

## Medlem av PGDIS (David Cram) om mosaikk {.smaller}
- Hvordan definere cut-off for â€œlav-â€ og â€œhÃ¸yâ€-gradig mosaikk: Â 
  - Alt. 1: bruke 50% som cut offÂ 
  - Alt. 2 er Ã¥ ta stÃ¸ynivÃ¥ satt av laboratoriet til betrakning. Â 
- Hvis stÃ¸ygrense er 20% for Ã¥ definere euploid vil:Â 
  - MÃ¥ling av 30% kan vÃ¦re sÃ¥ hÃ¸y som 50% eller lav som 10%Â 
  - MÃ¥ling av 40% kan vÃ¦re sÃ¥ hÃ¸y som 60% eller lav som 20%Â 
  - MÃ¥ling av 50% kan vÃ¦re sÃ¥ hÃ¸y som 70% eller lav som 30%Â 

![](transfer_priority.jpg)


## Mosasic transfer

- \>99% of live births from mosaic embryos transfer have no detectable abnormalities (Note the prerequisites of ongoing
pregnancy, i.e. no implantation failure, no miscarriage)
- Low-level mosaicism has a better outcome for implantation and pregnancy. But mosiac level "currenly" does not predict
the risk of being in the <1% of live births with abnormalities.


## Oversikt platformer
- PGT-A: trenger kun kopitall, vanligvis med lav-dekning sekvensering (<0.1XÂ dekning), ca 10Mb stÃ¸rrelseÂ Â 
- PGT-SR: lav-dekning sekvensering kan detektere ubalanser. **Trenger SNP-analyse** for Ã¥ skille bÃ¦rer fra normaleÂ 
- PGT-M: linkage eller **SNP-analyse** (haplotyping eller direkte deteksjon av mutasjonen)Â 
- PGT-P: trenger **SNP-analyse**
- PGT-WGS: alt over, trenger **SNP-analyse**


## PGT metoder
###### SNP array Genotyping 
Karyomapping, Haplarithmisis. High throughput SNP array, HaploSew, APCAD, Genome pridication PGT-PS, Hapltype-Aware, Whole genome prediction 


###### NGS genotyping
 PGT Complete, One PGT, Genotyping by sequencing, Cheb et al., HaploPGT, S-HaploSeek 


###### Sekvensering og target SNPs
PGT-Seq (Revvity), OneGene PGT


## UtfÃ¸rer WGS embryo screening  {.smaller}

- Gattaca Genomics (Florida, USA) 
- Orchid: genpanel med 1,400 gener for arvet patogene sykdommer og polygen risiko) 
- Panacea â€“ GenomeScreen TM: >2,500 sykdomsfremkallende gener for arvelige eller nye de novo-mutasjoner (GenEmbryomics/Progensis Inc) 
  - Foredlere ved x30 dybde og embryoer ved 50x dybde 
  - Omfattende variant filtrering for Ã¥ eliminere FP 
  - Variant annotering utfÃ¸rt fra >50 annoteringskilder, algoritmer for prediksjon av patogenisitet, og ACMG guidelines 
  - Benchmarking: Genome in a Bottle, flow-sorted GIAB celle linje, sammenlignet gDNA og amplifisert DNA (RepliG), vurdert med hap.py/VCFEval (Conrad Nat. Genet. (2011)) 
  - Binning approach (hadde problemer med targeted CNV) 
  - De nova mutasjoner: nÃ¸yaktighet beregnet etter filtrering men fÃ¸r annotatering 
  - niPGT: lav og variable DNA fragmenter --> ikke sÃ¥ robust


## Quality in IVF

- Juno Genetics (v/Dagan Wells) tar video av overfÃ¸ringer.
- Cytogenomix laboratory in Malaysia: UtfÃ¸rer shipping validation for IVF-lab som har forhÃ¸yet amplifiseringsfeil.Â 
- For NGS-basert metode:Â amplifisere mtDNA fra WGA-produkt (mtDetect Web App, skybasert m/server i USA).

## 
![](IMG_20240508_081023.jpg) 

## 
![](IMG_20240508_081206.jpg) 

## 
![](IMG_20240508_081312.jpg) 

## 
![](IMG_20240508_081511.jpg) 

## 
![](IMG_20240508_081648.jpg) 

## 
![](IMG_20240508_081754.jpg) 

## 
![](IMG_20240508_082146.jpg) 

## 
![](IMG_20240508_082337.jpg) 

## 
![](IMG_20240508_082607.jpg) 

## 
![](IMG_20240508_082734.jpg) 

## 
![](IMG_20240508_083011.jpg) 


## de novo mutations or incomplete pedigree

- Nesten ingen som gjÃ¸r dette per i dag, var diskusjoner om hvorvidt man skal begynne Ã¥ rapportere dette. Joris fra Leuven snakket om dette. Hvis vi begynner Ã¥ rapportere dette for embryo vil det vÃ¦re et paradigmeskifte. De Novo krever sÃ¥ mange som mulig embryobiopsier for Ã¥ skille ulike haplotyper.
- Hva ender man til slutt med Ã¥ kunne sette inn ved WES/WGS for DeNovo mutasjoner? 
- Long-read sequencing (and direct haplotyping) when incomplete pedigree, de novo mutations (Yikon).

## AI
#### re-classification of mosaic embryos (CooperSurgical)
- Mosasic Resolution by Decompositon 
- Clinical and theoretical decomposition to estimate mosaicism
- Copy number variation (CNV) and allelic balance

#### Grading/Selection Embryos


## 
![](IMG_20240507_121808.jpg) 

## 
![](IMG_20240507_122845.jpg) 

## Non-invasive PGT (niPGT)
- During in vitro development, mostly from day 4 to 6, embryo cell-free DNA (cfDNA) is released to the culture medium, with higher concentrations as the number of cells increase at blastocyst.
- informativity rates on D6: 98.8% (D5: 81.8%)
- ploidy concordance TE on D6: 89.1% (D5: 76%)
- concordance rate with full frozen blastocyst/ICM: up to 93.7% D6/7


## PGT-A
PGTai 2.0 ([CooperSurgical]{style="color:blue;"}) VS 
PGTseq-A ([JunoGenetis]{style="color:blue;"}) VS 
PG-Seq Rapid v2 Kit ([Revvit]{style="color:blue;"})

PGTseq-A:
[NGS of thousands of sites on each chromosome to get accurate copy number information and SNPs]{style="font-size: 0.4em;"}

::: {.r-stack}

![](copy_number.png){.fragment }

![](snps.png){.fragment }
:::

## PGT-A
PGTai 2.0 (CooperSurgical) VS PGTseq-A (JunoGenetis)

PGTai 2.0: [Also NGS and combines copy number information with SNPs, but powered by AI]{style="font-size: 0.5em;"}
![](PGTai2.0.png)

## 
![](IMG_20240506_164838.jpg) 

## 
![](IMG_20240506_165126.jpg) 

## 
![](IMG_20240508_083335.jpg) 

## 
![](IMG_20240508_083812.jpg) 

## 
![](IMG_20240508_084053.jpg) 

## 
![](IMG_20240508_084201.jpg) 

## 
![](IMG_20240508_084333.jpg) 

## 
![](IMG_20240508_084537.jpg) 

## 
![](IMG_20240508_084634.jpg) 

## 
![](IMG_20240508_084708.jpg) 

## 
![](IMG_20240508_102059.jpg) 

## 
![](IMG_20240508_121754.jpg) 

## 
![](IMG_20240508_122130.jpg) 

## 
![](IMG_20240508_122241.jpg) 

## 
![](IMG_20240508_122331.jpg) 

## 
![](IMG_20240508_122523.jpg) 

## 
![](IMG_20240508_122633.jpg) 

## 
![](IMG_20240508_122838.jpg) 

## 
![](IMG_20240508_123015.jpg) 

## 
![](IMG_20240508_123122.jpg)


## Kontaktpersoner
- *Carmen* fra iGenomix Valencia
- *Edith Coonen* (fikk info om at hun var go-to for PGT-SR)
- *David Kubicek* Poster 29
- *Aaron Chen* fra Malaysia som har brukt Karyomapping og Embryomap i mange Ã¥r
- *Silja Lu* fra Yikon (lusijia@yikongenoics.com)


##
::: {.r-stack}
![](threeofus.jpg){.fragment .r-stretch }

![](discussion.jpeg){.fragment .r-stretch}

![](ask.jpg){.fragment .r-stretch }

![](lunch.jpg){.fragment .r-stretch }

![](queen_come.jpg){.fragment .r-stretch }

![](queen1.jpg){.fragment .r-stretch }

![](dance.jpg){.fragment .r-stretch }

:::

